Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 10/20 | 0.53 |
| ▸ | GRM5 | P41594 | 9/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31702585 | 0.89 | GRM1 (0.49) | GRM1GRM5TRPV1CYP11B2TNK2 | |
| SCHEMBL13977697 | 0.85 | TRPV1 (0.58) | GRM1GRM5TRPV1CYP11B2TNK2 | |
| Methyl Alcohol SCHEMBL23277090 | 0.84 | TRPV1 (0.57) | GRM1GRM5TRPV1CYP11B2TNK2 | |
| SCHEMBL64701 | 0.81 | GRM1 (0.55) | GRM1GRM5CYP11B2TNK2PDK4 | |
| SCHEMBL1764228 | 0.81 | PDK4 (0.52) | GRM1GRM5PDK4SOS1 | |
| SCHEMBL1458617 | 0.80 | GRM5 (0.63) | GRM1GRM5TRPV1TNK2PDK4 | |
| SCHEMBL23705785 | 0.79 | GRM5 (0.57) | GRM1GRM5TRPV1CYP11B2TNK2 | |
| SCHEMBL16836113 | 0.79 | GRM1 (0.49) | GRM1GRM5CYP11B2TNK2PDK4 | |
| SCHEMBL16340041 | 0.78 | GRM1 (0.57) | GRM1GRM5CYP11B2PDK4 | |
| SCHEMBL22328950 | 0.78 | GRM1 (0.57) | GRM1GRM5TRPV1CYP11B2TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001893-A1 | SMALL MOLECULE MODULATORS OF STAT6 | GILEAD SCIENCES INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250320205-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001893-A1 | SMALL MOLECULE MODULATORS OF STAT6 | STAT6, NCOR1, NCOR2 | GRM1 521/4885GRM5 1394/4885TRPV1 2252/4885 |
| US-20250320205-A1 | STAT6 DEGRADERS | STAT6, STAT1, STAT5B | GRM1 4713/4885GRM5 4508/4885TRPV1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.